Search Results
158 items found for "IJzerman AP"
- Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors
We subsequently created a ranking of high scoring GPCRs, using a multi-objective approach (Pareto Front Our approach was confirmed by re-discovery of established cancer targets such as the LPA and mGlu receptor B J , Gorostiola González M , Wang X , van Vlijmen HWT , Jespers W , Gutiérrez-de-Terán H , Ye K , IJzerman AP , Heitman LH , van Westen GJP.
- Ep 140 with Dr Alix A J Rouault
Further, I applied to create a scientific session at the American Physiology Summit (APS) 2024 dedicated Our session was picked up by the APS.
- Stimulation of ectopically expressed muscarinic receptors induces IFN-γ but suppresses IL-2 production by inhibiting activation of pAKT pathways in primary T cells
Stimulation of muscarinic receptors induced strong nuclear translocation of NFAT and NFκB and activated AP
- Applying Pharmacology to Drug Discovery | Dr. GPCR Ecosystem
Applying Pharmacology to Drug Discovery Dr. My interests are in receptor theory, pharmacology applied to drug discovery and allosteric protein function
- Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer
Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis Furthermore, we examined the effects of GPR37 on tumor cell apoptosis and invasion. that GPR37 positively regulates NSCLC cell invasion, migration, and proliferation, suppresses cell apoptosis observed that GPR37 knockdown suppresses NSCLC cell invasion, migration, and proliferation, promotes cell apoptosis
- Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach
GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach Among the five somatostatin receptors, SST2 and SST3 are associated with apoptosis and cell cycle arrest
- CircFKBP5 Suppresses Apoptosis and Inflammation and Promotes Osteogenic Differentiation
< GPCR News < GPCRs in Oncology and Immunology CircFKBP5 Suppresses Apoptosis and Inflammation and Promotes Materials and methods: The viability and apoptosis of human DPSCs (hDPSCs) were determined using Cell expression was decreased in hDPSCs and, functionally, reexpression of circFKBP5 attenuated LPS-induced apoptosis Conclusions: CircFKBP5 could protect against LPS-induced apoptosis, inflammation, and osteogenic differentiation
- Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling
< GPCR News < GPCRs in Oncology and Immunology Regulator of G protein signaling 16 restrains apoptosis factors of CRC and the underlying mechanisms would offer potential therapeutic strategies for clinical application demonstrated that RGS16 promoted the CRC progression, knockdown of RGS16 led to significantly increased apoptosis Mechanistically, RGS16 restrained JNK/P38-mediated apoptosis in CRC cells through disrupting the recruitment
- The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis
chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody linked to a microtubule-disrupting agent, has been approved We evaluated a new effective combination partner of BV using non-clinical approaches that could potentially Apoptotic effects of the synergistic partner of BV were further investigated in vitro and in vivo using Further investigations in vitro and in vivo revealed that the levels of an anti-apoptotic protein, Bcl
- Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways
Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways Published date October 31, 2023 Abstract adenocarcinoma (PDAC) continues to present a formidable clinical challenge, demanding innovative therapeutic approaches Here we describe drug effects on pathways associated with cell cycle, DNA damage response (DDR), and apoptosis Drug combination effects on protein changes in the cell cycle- and apoptosis pathways contribute to the This approach provides a quantitative mechanistic framework for evaluating drug-drug interactions in
- Metallo-protease Peptidase M84 from Bacillusaltitudinis induces ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1
Oncology and Immunology Metallo-protease Peptidase M84 from Bacillusaltitudinis induces ROS-dependent apoptosis This metallo-protease had no discernible impact on normal cell survival, but it specifically induced apoptosis This evoked apoptotic death of the ovarian cancer cells through the intrinsic route. Collectively, our findings suggested that Peptidase M84 triggered PAR-1-mediated oxidative stress to act as an apoptosis
- Principles of Pharmacology in Drug Discovery I | Dr. GPCR Ecosystem
Application of this knowledge to determine the mechanism of action of new GPCR ligands. My interests are in receptor theory, pharmacology applied to drug discovery and allosteric protein function
- Advanced data analysis for GPCR pharmacology | Dr. GPCR Ecosystem
Appreciating the practical realities, limitations, and tradeoffs of GPCR data analysis. , and communicate GPCR pharmacology data analysis to a high level, as well as expertise that can be applied with numerous pharmaceutical, biotech, life science and academic organizations in understanding and applying Sam specializes in kinetic analysis of drug action and is known for applying binding and signaling kinetics
- Principles of Pharmacology in Drug Discovery II | Dr. GPCR Ecosystem
Candidate Selection This course continues with the basics learned in Course 1 and extends the ideas to apply Registrants will learn: The powerful applications of new cellular assays to determine GPCR ligand behavior Lecture 3: The Application of GPCR Ligand Kinetics to Candidate Design. My interests are in receptor theory, pharmacology applied to drug discovery and allosteric protein function
- Dr. GPCR Podcast Audience-Survey | Dr. GPCR Ecosystem
I really appreciate the way the podcast educates and mentors, particularly towards junior scientists
- Classified News | Dr. GPCR Ecosystem
learning Read More December 1, 2024 Neuronal cell populations in circumoral nerve ring of sea cucumber Apostichopus
- Ep 109 with Dr. Katarina Nemec
I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets I am continuing with the development of advanced screening approaches in the Madan Babu lab to progress I want to combine experimental approaches with data-driven discovery and adopt data science methodology
- Ep 153 with Dr Jacek Mokrosiński
experiences with name mispronunciations, cultural differences, and the importance of a multidisciplinary approach They also discussed their professional backgrounds, highlighting the benefits of a multidisciplinary approach They also shared their appreciation for documentaries showcasing manufacturing processes and the value the value of these interactions for professional growth and encouraged others to adopt a proactive approach
- Ep 50 with Dr. Thomas P. Sakmar
After moving to Rockefeller University with a Howard Hughes Medical Institute appointment, Tom advanced early use of computational homology modeling, molecular dynamics simulations and coarse-grain sampling approaches Early applications included “targeted photo-crosslinking,” and more recently, the parallel development
- Ep 60 with Dr. Josephine (Pina) Cardarelli
She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. interferon-alpha receptor project, licensed to AstraZeneca (Saphnelo™ Anifrolumab) that has just received FDA approval
- Ep 83 with Dr. Jean-Philippe Pin
modulation and activation mechanism of this family of G protein-coupled receptors using innovative approaches
- Ep 144 with Dr Aurélien Rizk
the development of a technology platform deciphering cell signaling pathways combined with AI-based approaches They highlighted that while there was a time when biology lagged due to the lack of appropriate tools They also touched upon the transferability of this approach across different systems, which Yamina found Berchiche and Aurelien Rizk discussed the complexities of GPCRs within cells and the potential for applying Academia to Biotech: Strategic Planning and Interdisciplinary Approach Yamina Berchiche and Aurelien
- Ep 87 with Dr. Bianca Plouffe
In 2018, Bianca was appointed Vice-Chancellor’s Fellow at Queen’s University Belfast to develop her research
- Ep 85 with Nicholas Holliday
studies and subsequent postdoctoral work that led to Nick's interest in peptide messengers regulating appetite
- Ep 146 with Dr Michael Feigin
in breast cancer pathogenesis, using mouse models, three-dimensional cell culture and computational approaches identifying GPCRs expressed in cancer cells but not in normal ones, and commended Mike's innovative approach Yamina emphasized the importance of thorough preparation and planning before applying for faculty positions Mike shared his strategy of developing preliminary projects and gathering data to strengthen his application moments in his scientific journey, including the discovery of RGS proteins and its impact on his research approach
- Ep 73 with Dr. Aylin Hanyaloglu
mechanisms regulating GPCR activity, including spatial control of GPCR signaling and receptor crosstalk, and applying
- Ep 154 with Dr Badr Sokrat
mentioned the importance of careful communication, especially when working with a boss who has a different approach
- GPCR Retreat 2023 - Part I
Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab